schliessen

Filtern

 

Bibliotheken

RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer ( RAD52 Polymorphisms and Response to Platinum Drugs)

RAD52 is an important but not well characterized homologous recombination repair gene that can bind to single-stranded DNA ends and mediate the DNA-DNA interaction necessary for the annealing of complementary DNA strands. To evaluate the role of RAD52 variants in the response of tumor cells to plati... Full description

Journal Title: 2012 Vol.7(11), p.e50461
Main Author: Shi, Ting-Yan
Other Authors: Yang, Gong , Tu, Xiao-Yu , Yang, Jing-Min , Qian, Ji , Wu, Xiao-Hua , Zhou, Xiao-Yan , Cheng, Xi , Wei, Qingyi
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0050461
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: plos10.1371/journal.pone.0050461
title: RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer ( RAD52 Polymorphisms and Response to Platinum Drugs)
format: Article
creator:
  • Shi, Ting-Yan
  • Yang, Gong
  • Tu, Xiao-Yu
  • Yang, Jing-Min
  • Qian, Ji
  • Wu, Xiao-Hua
  • Zhou, Xiao-Yan
  • Cheng, Xi
  • Wei, Qingyi
subjects:
  • Research Article
  • Biology
  • Medicine
  • Genetics And Genomics
  • Public Health And Epidemiology
  • Molecular Biology
  • Computational Biology
  • Oncology
  • Biophysics
  • Biochemistry
ispartof: 2012, Vol.7(11), p.e50461
description: RAD52 is an important but not well characterized homologous recombination repair gene that can bind to single-stranded DNA ends and mediate the DNA-DNA interaction necessary for the annealing of complementary DNA strands. To evaluate the role of RAD52 variants in the response of tumor cells to platinum agents, we investigated their associations with platinum resistance and prognosis in cervical cancer patients. We enrolled 154 patients with cervical squamous cell carcinoma, who had radical surgery between 2008 and 2009, and genotyped three potentially functional RAD52 variants by the SNaPshot assay. We tested in vitro platinum resistance and RAD52 expression by using the MTT and immunohistochemistry methods, respectively. In 144 cases who had genotyping data, we found that both the rs1051669 variant and RAD52 protein expression were significantly associated with carboplatin resistance ( P  = 0.024 and 0.028, respectively) and rs10774474 with nedaplatin resistance ( P  = 0.018). The rs1051669 variant was significantly associated with RAD52 protein expression (adjusted OR = 4.7, 95% CI = 1.4−16.1, P  = 0.013). When these three RAD52 variants were combined, progression-free survival was lower in patients who carried at least one (≥1) variant allele compared to those without any of the variant alleles ( P  = 0.047). Therefore, both RAD52 variants and protein expression can predict platinum resistance, and RAD52 variants appeared to predict prognosis in cervical cancer patients. Large studies are warranted to validate these findings.
language: eng
source:
identifier: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0050461
fulltext: fulltext
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID1042658771
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1371/journal.pone.0050461
sourceidplos
recordidTN_plos10.1371/journal.pone.0050461
sourcesystemPC
pqid1350911698
galeid477004088
display
typearticle
titleRAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer ( RAD52 Polymorphisms and Response to Platinum Drugs)
creatorShi, Ting-Yan ; Yang, Gong ; Tu, Xiao-Yu ; Yang, Jing-Min ; Qian, Ji ; Wu, Xiao-Hua ; Zhou, Xiao-Yan ; Cheng, Xi ; Wei, Qingyi
contributorHawkins, Shannon M. (Editor)
ispartof2012, Vol.7(11), p.e50461
identifierE-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0050461
subjectResearch Article ; Biology ; Medicine ; Genetics And Genomics ; Public Health And Epidemiology ; Molecular Biology ; Computational Biology ; Oncology ; Biophysics ; Biochemistry
descriptionRAD52 is an important but not well characterized homologous recombination repair gene that can bind to single-stranded DNA ends and mediate the DNA-DNA interaction necessary for the annealing of complementary DNA strands. To evaluate the role of RAD52 variants in the response of tumor cells to platinum agents, we investigated their associations with platinum resistance and prognosis in cervical cancer patients. We enrolled 154 patients with cervical squamous cell carcinoma, who had radical surgery between 2008 and 2009, and genotyped three potentially functional RAD52 variants by the SNaPshot assay. We tested in vitro platinum resistance and RAD52 expression by using the MTT and immunohistochemistry methods, respectively. In 144 cases who had genotyping data, we found that both the rs1051669 variant and RAD52 protein expression were significantly associated with carboplatin resistance ( P  = 0.024 and 0.028, respectively) and rs10774474 with nedaplatin resistance ( P  = 0.018). The rs1051669 variant was significantly associated with RAD52 protein expression (adjusted OR = 4.7, 95% CI = 1.4−16.1, P  = 0.013). When these three RAD52 variants were combined, progression-free survival was lower in patients who carried at least one (≥1) variant allele compared to those without any of the variant alleles ( P  = 0.047). Therefore, both RAD52 variants and protein expression can predict platinum resistance, and RAD52 variants appeared to predict prognosis in cervical cancer patients. Large studies are warranted to validate these findings.
languageeng
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Shi, Ting-Yan
1Yang, Gong
2Tu, Xiao-Yu
3Yang, Jing-Min
4Qian, Ji
5Wu, Xiao-Hua
6Zhou, Xiao-Yan
7Cheng, Xi
8Wei, Qingyi
9Hawkins, Shannon M. (Editor)
titleRAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer ( RAD52 Polymorphisms and Response to Platinum Drugs)
descriptionRAD52 is an important but not well characterized homologous recombination repair gene that can bind to single-stranded DNA ends and mediate the DNA-DNA interaction necessary for the annealing of complementary DNA strands. To evaluate the role of RAD52 variants in the response of tumor cells to platinum agents, we investigated their associations with platinum resistance and prognosis in cervical cancer patients. We enrolled 154 patients with cervical squamous cell carcinoma, who had radical surgery between 2008 and 2009, and genotyped three potentially functional RAD52 variants by the SNaPshot assay. We tested in vitro platinum resistance and RAD52 expression by using the MTT and immunohistochemistry methods, respectively. In 144 cases who had genotyping data, we found that both the rs1051669 variant and RAD52 protein expression were significantly associated with carboplatin resistance ( P  = 0.024 and 0.028, respectively) and rs10774474 with nedaplatin resistance ( P  = 0.018). The rs1051669 variant was significantly associated with RAD52 protein expression (adjusted OR = 4.7, 95% CI = 1.4−16.1, P  = 0.013). When these three RAD52 variants were combined, progression-free survival was lower in patients who carried at least one (≥1) variant allele compared to those without any of the variant alleles ( P  = 0.047). Therefore, both RAD52 variants and protein expression can predict platinum resistance, and RAD52 variants appeared to predict prognosis in cervical cancer patients. Large studies are warranted to validate these findings.
subject
0Research Article
1Biology
2Medicine
3Genetics And Genomics
4Public Health And Epidemiology
5Molecular Biology
6Computational Biology
7Oncology
8Biophysics
9Biochemistry
general
010.1371/journal.pone.0050461
1English
sourceidplos
recordidplos10.1371/journal.pone.0050461
issn
01932-6203
119326203
rsrctypearticle
creationdate2012
recordtypearticle
addtitleRAD52 Polymorphisms and Response to Platinum Drugs
searchscopeplos
scopeplos
lsr30VSR-Enriched:[pqid, galeid]
sort
titleRAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer ( RAD52 Polymorphisms and Response to Platinum Drugs)
authorShi, Ting-Yan ; Yang, Gong ; Tu, Xiao-Yu ; Yang, Jing-Min ; Qian, Ji ; Wu, Xiao-Hua ; Zhou, Xiao-Yan ; Cheng, Xi ; Wei, Qingyi
creationdate20121129
facets
frbrgroupid8817036719120781618
frbrtype5
languageeng
creationdate2012
topic
0Research Article
1Biology
2Medicine
3Genetics And Genomics
4Public Health And Epidemiology
5Molecular Biology
6Computational Biology
7Oncology
8Biophysics
9Biochemistry
collectionPLoS
prefilterarticles
rsrctypearticles
creatorcontrib
0Shi, Ting-Yan
1Yang, Gong
2Tu, Xiao-Yu
3Yang, Jing-Min
4Qian, Ji
5Wu, Xiao-Hua
6Zhou, Xiao-Yan
7Cheng, Xi
8Wei, Qingyi
9Hawkins, Shannon M.
toplevelpeer_reviewed
frbr
t2
k12012
k219326203
k310.1371/journal.pone.0050461
k47
k511
k650461
k8rad52 variants predict platinum resistance prognosis of cervical cancer
k9rad52variantspredictancer
k12rad52variantspredictplati
k15tingyanshi
k16shitingyan
delivery
delcategoryRemote Search Resource
fulltextfulltext
ranking
booster11
booster21
pcg_typepublisher
addata
aulast
0Shi
1Yang
2Tu
3Qian
4Wu
5Zhou
6Cheng
7Wei
8Hawkins
aufirst
0Ting-Yan
1Gong
2Xiao-Yu
3Jing-Min
4Ji
5Xiao-Hua
6Xiao-Yan
7Xi
8Qingyi
9Shannon M.
au
0Shi, Ting-Yan
1Yang, Gong
2Tu, Xiao-Yu
3Yang, Jing-Min
4Qian, Ji
5Wu, Xiao-Hua
6Zhou, Xiao-Yan
7Cheng, Xi
8Wei, Qingyi
addauHawkins, Shannon M.
atitleRAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer ( RAD52 Polymorphisms and Response to Platinum Drugs)
risdate20121129
volume7
issue11
spagee50461
pagese50461
eissn1932-6203
genrearticle
ristypeJOUR
abstractRAD52 is an important but not well characterized homologous recombination repair gene that can bind to single-stranded DNA ends and mediate the DNA-DNA interaction necessary for the annealing of complementary DNA strands. To evaluate the role of RAD52 variants in the response of tumor cells to platinum agents, we investigated their associations with platinum resistance and prognosis in cervical cancer patients. We enrolled 154 patients with cervical squamous cell carcinoma, who had radical surgery between 2008 and 2009, and genotyped three potentially functional RAD52 variants by the SNaPshot assay. We tested in vitro platinum resistance and RAD52 expression by using the MTT and immunohistochemistry methods, respectively. In 144 cases who had genotyping data, we found that both the rs1051669 variant and RAD52 protein expression were significantly associated with carboplatin resistance ( P  = 0.024 and 0.028, respectively) and rs10774474 with nedaplatin resistance ( P  = 0.018). The rs1051669 variant was significantly associated with RAD52 protein expression (adjusted OR = 4.7, 95% CI = 1.4−16.1, P  = 0.013). When these three RAD52 variants were combined, progression-free survival was lower in patients who carried at least one (≥1) variant allele compared to those without any of the variant alleles ( P  = 0.047). Therefore, both RAD52 variants and protein expression can predict platinum resistance, and RAD52 variants appeared to predict prognosis in cervical cancer patients. Large studies are warranted to validate these findings.
copSan Francisco, USA
pubPublic Library of Science
doi10.1371/journal.pone.0050461
oafree_for_read
date2012-11-29